Reversal of Multi-drug Resistance by PSUPER-shRNA-mdr1 in Vivo and in Vitro

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2009 Jan 20

PMID 19152447

Citations 7

Authors

Guang-Dong Pan

Jian-qing Yang

Lv-Nan Yan

Guang-Ping Chu

Qiang Liu

Yi Xiao

Lin Yuan

Affiliations

Soon will be listed here.

Abstract

Aim: To explore the possibility of reversing multi-drug resistance (MDR) to HepG2/mdr1 in vitro and in vivo with RNA interference (RNAi).

Methods: HepG2/mdr1 was obtained by cloning the whole gene mdr1 into HepG2 cells. shRNA targeting sequence was designed to be homologous to the P-gp encoding MDR1 mRNA consensus sequence. pSUPER-shRNA/mdr1 was constructed using the enzyme-digested technique. HepG2/mdr1 cells were transfected with vectors of pSUPER-shRNA/mdr1 to measure their efficacy by real-time PCR for mdr1 mRNA, flow cytometry (FCM) for P-gp expression, and Rhodamine efflux, MTT method for HepG2/mdr1 function, respectively. In vivo, mice tumors were treated by injecting pSUPER-shRNA/mdr1 in situ and into intra-abdominal cavity. Tumors were collected to create cell suspension and cryosections after chemotherapy with adriamycin and mytomycin. The cell suspension was incubated in RPMI-1640 supplemented with G418 to screen stable cells for appreciating the reversal of MDR. Cryosections were treated with immunohistochemistry technique to show the effectiveness of transfection and the expression of P-gp.

Results: pSUPER-shRNA/mdr1 was successfully constructed, which was confirmed by sequencing. The MDR phenotype of HepG2/mdr1 was decreased significantly in vitro transfection. HepG2/mdr1 showing its MDR was reversed notably in P-gp expression (11.0% vs 98.2%, P<0.01). Real-time PCR showed that mRNA/mdr1 was lower in test groups than in control groups (18.73+/-1.33 vs 68.03+/-2.21, P<0.001). Compared with HepG2, the sensitivity of HepG2/mdr1 and HepG2/mdr1-dsRNA cells to ADM was decreased by 1.64 times and 15.6 times, respectively. The accumulation of DNR in positive groups was decreased evidently. In vivo, the p-gp expression in positive groups was significantly lower than that in control groups (65.1% vs 94.1%, P<0.05). The tumor suppressing rate in test groups was 57.8%. After chemotherapy, the growth rate in test groups was lower than that in control groups (700.14+/-35.61 vs 1659.70+/-152.54, P<0.05). Similar results were also observed under fluorescence microscope, and confirmed by Image-Pro Plus 4.5 analysis.

Conclusion: pSUPER-shRNA/mdr1 vector system allows simple, stable and durable nonviral knockdown of P-gp by RNAi in malignant cells and animals to restore their sensitivity to adriamycin.

Citing Articles

Effect of intravitreal conbercept injection on VEGF-A and -B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy.

Zhang Y, Gao Z, Zhang X, Yuan Z, Ma T, Li G Exp Ther Med. 2021; 21(4):332.

PMID: 33732305 PMC: 7903486. DOI: 10.3892/etm.2021.9763.

P-glycoprotein attenuates DNA repair activity in multidrug-resistant cells by acting through the Cbp-Csk-Src cascade.

Lin L, Wu M, Pidugu V, Ho I, Su T, Lee T Oncotarget. 2017; 8(28):45072-45087.

PMID: 28178691 PMC: 5542168. DOI: 10.18632/oncotarget.15065.

Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.

Zhang X, Zhang B, Liu J, Liu J, Li C, Dong W Sci Rep. 2015; 5:7835.

PMID: 25644501 PMC: 4314651. DOI: 10.1038/srep07835.

Methylation of SFRP5 is related to multidrug resistance in leukemia cells.

Wang H, Wang X, Hu R, Yang W, Liao A, Zhao C Cancer Gene Ther. 2014; 21(2):83-9.

PMID: 24434572 DOI: 10.1038/cgt.2013.87.

Coordinated targeting of the EGFR signaling axis by microRNA-27a*.

Wu X, Bhayani M, Dodge C, Nicoloso M, Chen Y, Yan X Oncotarget. 2013; 4(9):1388-98.

PMID: 23963114 PMC: 3824521. DOI: 10.18632/oncotarget.1239.

References

Liu F, Song Y, Liu D . Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999; 6(7):1258-66. DOI: 10.1038/sj.gt.3300947. View

Lewis D, Hagstrom J, Loomis A, Wolff J, Herweijer H . Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet. 2002; 32(1):107-8. DOI: 10.1038/ng944. View

Fuchs B, Zhang K, Schabel A, Bolander M, Sarkar G . Identification of twenty-two candidate markers for human osteogenic sarcoma. Gene. 2001; 278(1-2):245-52. DOI: 10.1016/s0378-1119(01)00731-4. View

Karkare S, Daniel S, Bhatnagar D . RNA interference silencing the transcriptional message: aspects and applications. Appl Biochem Biotechnol. 2004; 119(1):1-12. DOI: 10.1385/abab:119:1:01. View

Gan H, Zhang G, Zhao J, Zhang F, Bu L, Yang S . Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors. Chin Med J (Engl). 2005; 118(11):893-902. View

Yague E, Higgins C, Raguz S . Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther. 2004; 11(14):1170-4. DOI: 10.1038/sj.gt.3302269. View

Wang H, Lee H . [Surgical treatment of hepatocellular carcinoma]. Korean J Gastroenterol. 2005; 45(4):247-57. View

Holm P, Lage H, Bergmann S, Jurchott K, Glockzin G, Bernshausen A . Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res. 2004; 64(1):322-8. DOI: 10.1158/0008-5472.can-0482-2. View

Elbashir S, Lendeckel W, Tuschl T . RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001; 15(2):188-200. PMC: 312613. DOI: 10.1101/gad.862301. View

10.

Aleman C, Annereau J, Liang X, Cardarelli C, Taylor B, Yin J . P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res. 2003; 63(12):3084-91. View

11.

Wu H, Hait W, Yang J . Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003; 63(7):1515-9. View

12.

Tuschl T . RNA interference and small interfering RNAs. Chembiochem. 2002; 2(4):239-45. DOI: 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.0.CO;2-R. View

13.

Pichler A, Zelcer N, Prior J, Kuil A, Piwnica-Worms D . In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res. 2005; 11(12):4487-94. DOI: 10.1158/1078-0432.CCR-05-0038. View

14.

Barton G, Medzhitov R . Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci U S A. 2002; 99(23):14943-5. PMC: 137524. DOI: 10.1073/pnas.242594499. View

15.

Brummelkamp T, Bernards R, Agami R . Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002; 2(3):243-7. DOI: 10.1016/s1535-6108(02)00122-8. View

16.

Borst P, Elferink R . Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002; 71:537-92. DOI: 10.1146/annurev.biochem.71.102301.093055. View

17.

Rubin Grandis J, Zeng Q, Drenning S . Epidermal growth factor receptor--mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope. 2000; 110(5 Pt 1):868-74. DOI: 10.1097/00005537-200005000-00016. View

18.

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

19.

Roninson I, Chin J, Choi K, Gros P, Housman D, Fojo A . Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A. 1986; 83(12):4538-42. PMC: 323769. DOI: 10.1073/pnas.83.12.4538. View

20.

Shi Z, Liang Y, Chen Z, Wang X, Wang X, Ding Y . Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther. 2005; 5(1):39-47. DOI: 10.4161/cbt.5.1.2236. View